20 Gene Model for Bladder Cancer
Author Information
Author(s): Dancik Garrett, Aisner Dara, Theodorescu Dan
Primary Institution: University of Colorado
Hypothesis
Can a 20 gene model predict nodal involvement in bladder cancer patients with muscle invasive tumors?
Conclusion
The 20 gene model can help identify bladder cancer patients who are at high risk for nodal involvement and may benefit from neoadjuvant therapy.
Supporting Evidence
- The model identified high, intermediate, and low risk groups with relative risks of 1.74, 1.05, and 0.74, respectively.
- Neoadjuvant chemotherapy has been shown to improve survival in patients with muscle invasive bladder cancer.
- The test can be applied to formalin-fixed paraffin embedded tissue, making it feasible for routine diagnostics.
Takeaway
This study created a test that looks at 20 genes to see if bladder cancer patients might have cancer spread to their lymph nodes, helping doctors decide on treatment.
Methodology
The model was developed using gene expression data from Affymetrix Human Genome U133A and U133 Plus 2.0 arrays and validated with independent datasets.
Potential Biases
Potential bias from gene profiling studies performed on small specimen sets.
Limitations
The test is not currently available in a clinical laboratory setting and has only one peer-reviewed publication.
Participant Demographics
Patients included in the study were diagnosed with muscle-invasive bladder cancer.
Statistical Information
P-Value
p < 0.025
Confidence Interval
95% CI, 1.03 – 2.93
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website